Recursion Pharmaceuticals (RXRX) Financials

$5.64 +0.13 (+2.36%)

Closing price 04/15/2025 04:00 PM Eastern

Extended Trading

$5.51 -0.13 (-2.30%)

As of 04/15/2025 07:59 PM Eastern

Annual Income Statements for Recursion Pharmaceuticals

This table shows Recursion Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2019	2020	2021	2022	2023	2024
Net Income / (Loss) Attributable to Common Shareholders	-62	-87	-186	-239	-328	-464
Consolidated Net Income / (Loss)	-62	-87	-186	-239	-328	-464
Net Income / (Loss) Continuing Operations	-62	-87	-186	-239	-328	-464
Total Pre-Tax Income	-62	-85	-186	-239	-332	-465
Total Operating Income	-62	-85	-183	-246	-350	-479
Total Gross Profit	2.32	3.96	10	-8.43	1.99	14
Total Revenue	2.32	3.96	10	40	45	59
Operating Revenue	2.32	3.96	10	40	45	59
Total Cost of Revenue	0.00	0.00	0.00	48	43	45
Operating Cost of Revenue	-	0.00	0.00	48	43	45
Total Operating Expenses	65	89	193	237	352	493
Selling, General & Admin Expense	19	25	58	82	111	178
Research & Development Expense	46	63	135	156	241	314
Total Other Income / (Expense), net	0.00	0.00	-3.70	6.25	18	14
Other Income / (Expense), net	-	-	-3.70	6.25	18	14
Income Tax Expense	-	-	0.00	0.00	-4.06	-1.13
Basic Earnings per Share	($2.87)	($3.99)	($1.49)	($1.36)	($1.58)	($1.69)
Weighted Average Basic Shares Outstanding	21.57M	21.78M	125.35M	175.54M	207.85M	274.21M
Diluted Earnings per Share	($2.87)	($3.99)	($1.49)	($1.36)	($1.58)	($1.69)
Weighted Average Diluted Shares Outstanding	21.57M	21.78M	125.35M	175.54M	207.85M	274.21M
Weighted Average Basic & Diluted Shares Outstanding	-	-	170.77M	191.23M	234.65M	401.99M

This table shows Recursion Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Income / (Loss) Attributable to Common Shareholders	-60	-57	-65	-77	-93	-93	-91	-98	-96	-179
Consolidated Net Income / (Loss)	-60	-57	-65	-77	-93	-93	-91	-98	-96	-179
Net Income / (Loss) Continuing Operations	-60	-57	-65	-77	-93	-93	-91	-98	-96	-179
Total Pre-Tax Income	-63	-55	-65	-77	-93	-97	-92	-98	-96	-179
Total Operating Income	-63	-61	-70	-82	-100	-99	-96	-101	-98	-184
Total Gross Profit	-2.25	2.84	-0.31	1.64	-0.34	1.01	2.63	5.22	14	-8.25
Total Revenue	13	14	12	11	11	11	14	14	26	4.55
Operating Revenue	13	14	12	11	11	11	14	14	26	4.55
Total Cost of Revenue	15	11	12	9.38	11	9.88	11	9.20	12	13
Operating Cost of Revenue	15	11	12	9.38	11	9.88	11	9.20	12	13
Total Operating Expenses	60	64	70	83	99	100	99	106	112	176
Selling, General & Admin Expense	19	20	23	28	29	30	31	32	38	77
Research & Development Expense	41	44	47	55	70	69	68	74	75	98
Total Other Income / (Expense), net	0.00	6.25	4.54	4.99	6.53	1.87	4.19	2.48	2.68	4.87
Other Income / (Expense), net	-	-	4.54	4.99	6.53	1.87	4.19	2.48	2.68	4.87
Income Tax Expense	-	-	0.00	0.00	0.00	-4.06	-0.78	-0.52	0.17	0.01
Basic Earnings per Share	($0.35)	($0.30)	($0.34)	($0.38)	($0.43)	($0.43)	($0.39)	($0.40)	($0.34)	($0.56)
Weighted Average Basic Shares Outstanding	173.44M	175.54M	191.62M	201.42M	214.33M	207.85M	236.02M	242.20M	282.58M	274.21M
Diluted Earnings per Share	($0.35)	($0.30)	($0.34)	($0.38)	($0.43)	($0.43)	($0.39)	($0.40)	($0.34)	($0.56)
Weighted Average Diluted Shares Outstanding	173.44M	175.54M	191.62M	201.42M	214.33M	207.85M	236.02M	242.20M	282.58M	274.21M
Weighted Average Basic & Diluted Shares Outstanding	189.56M	191.23M	192.36M	215.59M	216.62M	234.65M	237.66M	281.11M	286.64M	401.99M

This table details how cash moves in and out of Recursion Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2019	2020	2021	2022	2023	2024
Net Change in Cash & Equivalents	59	192	28	264	-158	202
Net Cash From Operating Activities	-57	-45	-159	-84	-288	-359
Net Cash From Continuing Operating Activities	-57	-45	-159	-84	-290	-359
Net Income / (Loss) Continuing Operations	-62	-87	-186	-239	-328	-464
Consolidated Net Income / (Loss)	-62	-87	-186	-239	-328	-464
Depreciation Expense	2.49	3.94	8.41	12	24	36
Non-Cash Adjustments To Reconcile Net Income	2.88	33	9.77	39	66	106
Changes in Operating Assets and Liabilities, net	-0.53	4.17	9.69	104	-53	-38
Net Cash From Investing Activities	-3.91	-8.74	-272	193	-10	260
Net Cash From Continuing Investing Activities	-3.91	-8.74	-272	193	-10	260
Purchase of Property, Plant & Equipment	-3.91	-5.83	-40	-37	-12	-14
Acquisitions	0.00	-3.50	0.00	-0.30	1.25	274
Sale and/or Maturity of Investments	0.00	0.60	69	231	0.48	0.00
Net Cash From Financing Activities	120	246	459	154	140	304
Net Cash From Continuing Financing Activities	120	246	459	154	140	304
Repayment of Debt	-11	-0.08	-13	-0.09	-0.77	-4.44
Issuance of Common Equity	0.07	0.68	471	154	141	309
Effect of Exchange Rate Changes	-	0.00	0.00	-0.31	0.19	-3.41

This table details how cash moves in and out of Recursion Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Change in Cash & Equivalents	0.78	94	-77	-66	-20	4.22	-95	177	-47	167
Net Cash From Operating Activities	-55	-45	-73	-67	-73	-74	-102	-82	-59	-115
Net Cash From Continuing Operating Activities	-55	-45	-73	-67	-73	-77	-102	-82	-59	-115
Net Income / (Loss) Continuing Operations	-60	-57	-65	-77	-93	-93	-91	-98	-96	-179
Consolidated Net Income / (Loss)	-60	-57	-65	-77	-93	-93	-91	-98	-96	-179
Depreciation Expense	2.99	3.21	3.73	5.54	7.58	7.55	7.38	8.97	7.20	13
Non-Cash Adjustments To Reconcile Net Income	-2.37	-114	0.55	2.77	6.82	56	4.49	3.98	31	67
Changes in Operating Assets and Liabilities, net	5.29	123	-12	0.95	5.70	-47	-23	2.37	-1.25	-16
Net Cash From Investing Activities	53	-7.98	-5.34	-2.05	-0.35	-2.49	-6.65	-4.18	-4.56	275
Net Cash From Continuing Investing Activities	53	-7.98	-5.34	-2.05	-0.35	-2.49	-6.65	-4.18	-4.56	275
Purchase of Property, Plant & Equipment	-8.26	-7.98	-5.18	-3.97	-0.75	-2.07	-6.65	-1.18	-4.56	-1.30
Acquisitions	-0.30	-	-0.17	1.92	-0.08	-0.42	0.00	-3.00	-	277
Net Cash From Financing Activities	2.34	147	1.92	3.79	54	81	14	263	16	11
Net Cash From Continuing Financing Activities	2.34	147	1.92	3.79	54	81	14	263	16	11
Repayment of Debt	-0.02	-0.02	-0.02	-0.02	-0.02	-0.69	-0.03	-0.03	-2.29	-2.10
Issuance of Common Equity	2.36	147	1.95	3.81	54	81	14	263	19	13
Effect of Exchange Rate Changes	-	-0.31	-0.00	0.18	-0.12	0.12	-0.22	-0.12	0.40	-3.47

This table presents Recursion Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2020	2021	2022	2023	2024
Total Assets	299	610	701	654	1,449
Total Current Assets	266	535	570	438	714
Cash & Equivalents	262	285	550	392	594
Restricted Cash	2.00	1.55	1.28	3.23	3.05
Accounts Receivable	0.16	9.09	2.75	3.09	49
Other Current Assets	2.16	7.51	16	40	68
Plant, Property, & Equipment, net	26	65	88	87	141
Total Noncurrent Assets	6.18	11	43	129	593
Noncurrent Note & Lease Receivables	-	-	-	0.00	26
Goodwill	0.80	0.80	0.80	52	149
Intangible Assets	1.69	1.39	1.31	36	336
Noncurrent Deferred & Refundable Income Taxes	-	-	-	0.00	1.93
Other Noncurrent Operating Assets	3.69	8.72	41	41	80
Total Liabilities & Shareholders' Equity	299	610	701	654	1,449
Total Liabilities	57	67	215	190	414
Total Current Liabilities	23	47	100	93	187
Short-Term Debt	1.07	0.09	0.10	0.04	8.43
Accounts Payable	1.07	2.82	4.59	3.95	22
Accrued Expenses	10	32	33	47	82
Current Deferred Revenue	10	10	57	36	62
Other Current Liabilities	0.47	1.42	5.95	6.12	14
Total Noncurrent Liabilities	33	21	115	97	226
Long-Term Debt	11	0.63	0.54	1.10	19
Noncurrent Deferred Revenue	19	11	70	51	119
Noncurrent Deferred & Payable Income Tax Liabilities	-	-	0.00	1.34	17
Other Noncurrent Operating Liabilities	-	0.00	44	43	72
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	-206	543	486	463	1,035
Total Preferred & Common Equity	-206	543	486	463	1,035
Total Common Equity	-206	543	486	463	1,035
Common Stock	7.31	943	1,125	1,431	2,474
Retained Earnings	-214	-400	-640	-968	-1,431
Accumulated Other Comprehensive Income / (Loss)	0.00	-0.13	-	0.00	-7.64

This table presents Recursion Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Total Assets	612	627	667	631	558	776	726
Total Current Assets	482	492	431	411	344	522	474
Cash & Equivalents	455	473	406	387	296	474	428
Restricted Cash	2.09	1.31	3.33	2.26	3.20	1.78	1.56
Accounts Receivable	12	2.06	3.05	3.16	2.60	2.53	2.26
Other Current Assets	13	16	19	18	41	44	43
Plant, Property, & Equipment, net	86	90	90	86	87	84	84
Total Noncurrent Assets	44	45	146	134	128	170	168
Noncurrent Note & Lease Receivables	-	-	-	-	-	29	27
Goodwill	0.80	0.80	61	53	52	52	52
Intangible Assets	1.46	1.32	43	39	33	38	34
Other Noncurrent Operating Assets	42	43	43	42	42	51	55
Total Liabilities & Shareholders' Equity	612	627	667	631	558	776	726
Total Liabilities	223	197	198	193	157	191	202
Total Current Liabilities	83	92	114	94	74	86	109
Short-Term Debt	0.10	0.66	0.68	0.70	0.06	8.11	8.22
Accounts Payable	3.89	4.25	2.09	4.27	5.12	3.76	2.26
Accrued Expenses	27	25	33	40	26	33	41
Current Deferred Revenue	47	58	73	44	37	32	50
Other Current Liabilities	5.54	4.44	5.22	5.36	6.06	8.61	8.23
Total Noncurrent Liabilities	140	105	84	99	83	105	93
Long-Term Debt	0.56	1.18	1.16	1.13	1.07	23	21
Noncurrent Deferred Revenue	94	57	32	51	37	29	16
Noncurrent Deferred & Payable Income Tax Liabilities	-	-	4.34	1.93	0.53	0.00	0.17
Other Noncurrent Operating Liabilities	46	47	46	44	44	53	57
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	388	430	469	438	401	584	525
Total Preferred & Common Equity	388	430	469	438	401	584	525
Total Common Equity	388	430	469	438	401	584	525
Common Stock	970	1,135	1,251	1,313	1,460	1,741	1,777
Retained Earnings	-582	-705	-782	-875	-1,059	-1,157	-1,252

This table displays calculated financial ratios and metrics derived from Recursion Pharmaceuticals' official financial filings.

Metric	2019	2020	2021	2022	2023	2024
Growth Metrics	-	-	-	-	-	-
Revenue Growth	0.00%	70.85%	156.89%	291.46%	11.88%	32.00%
EBITDA Growth	0.00%	-34.56%	-120.74%	-27.88%	-35.13%	-39.18%
EBIT Growth	0.00%	-35.51%	-120.39%	-28.42%	-38.69%	-39.94%
NOPAT Growth	0.00%	-35.51%	-116.01%	-34.44%	-42.46%	-36.83%
Net Income Growth	0.00%	-40.61%	-114.33%	-28.42%	-36.99%	-41.33%
EPS Growth	0.00%	-39.02%	62.66%	8.72%	-16.18%	-6.96%
Operating Cash Flow Growth	0.00%	20.41%	-249.38%	47.34%	-244.55%	-24.81%
Free Cash Flow Firm Growth	0.00%	0.00%	-224.40%	57.36%	-424.50%	-92.41%
Invested Capital Growth	0.00%	0.00%	605.01%	-285.61%	207.77%	566.12%
Revenue Q/Q Growth	0.00%	0.00%	-1.53%	38.83%	-5.88%	-9.73%
EBITDA Q/Q Growth	0.00%	0.00%	-30.84%	4.69%	-5.37%	-21.73%
EBIT Q/Q Growth	0.00%	0.00%	-30.04%	4.10%	-6.41%	-21.37%
NOPAT Q/Q Growth	0.00%	0.00%	-27.46%	1.59%	-12.16%	-21.52%
Net Income Q/Q Growth	0.00%	0.00%	-26.59%	3.01%	-12.14%	-22.74%
EPS Q/Q Growth	0.00%	0.00%	46.40%	-44.68%	-8.97%	-8.33%
Operating Cash Flow Q/Q Growth	0.00%	0.00%	-78.45%	16.42%	-11.35%	-13.01%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	21.89%	-12.72%	-108.80%
Invested Capital Q/Q Growth	0.00%	0.00%	147.54%	4.84%	38.98%	274.61%
Profitability Metrics	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	-21.16%	4.46%	23.12%
EBITDA Margin	-2,585.25%	-2,036.14%	-1,749.60%	-571.54%	-690.36%	-727.91%
Operating Margin	-2,692.58%	-2,135.66%	-1,795.79%	-616.74%	-785.33%	-814.09%
EBIT Margin	-2,692.58%	-2,135.66%	-1,832.18%	-601.05%	-745.10%	-789.93%
Profit (Net Income) Margin	-2,668.35%	-2,196.01%	-1,832.18%	-601.05%	-735.99%	-788.02%
Tax Burden Percent	99.10%	102.83%	100.00%	100.00%	98.78%	99.76%
Interest Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	-914.59%	0.00%	-9,745.16%	-125.44%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	-899.13%	0.00%	-9,727.57%	-98.80%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	867.08%	0.00%	9,676.04%	63.54%
Return on Equity (ROE)	0.00%	-35.95%	-47.51%	-46.56%	-69.12%	-61.90%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	-486.55%	0.00%	-543.95%	-273.23%
Operating Return on Assets (OROA)	0.00%	-28.34%	-41.03%	-36.52%	-49.02%	-44.22%
Return on Assets (ROA)	0.00%	-29.14%	-41.03%	-36.52%	-48.42%	-44.11%
Return on Common Equity (ROCE)	0.00%	30.64%	-20.38%	-46.56%	-69.12%	-61.90%
Return on Equity Simple (ROE_SIMPLE)	0.00%	42.18%	-34.35%	-49.29%	-70.79%	-44.81%
Net Operating Profit after Tax (NOPAT)	-44	-59	-128	-172	-245	-335
NOPAT Margin	-1,884.81%	-1,494.96%	-1,257.05%	-431.72%	-549.73%	-569.86%
Net Nonoperating Expense Percent (NNEP)	0.00%	-22.32%	-15.47%	-12.75%	-17.59%	-26.64%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-35.36%	-52.75%	-31.57%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	121.16%	95.54%	76.88%
SG&A Expenses to Revenue	817.21%	637.51%	566.73%	204.80%	248.62%	302.83%
R&D to Revenue	1,975.38%	1,598.16%	1,329.05%	390.77%	541.17%	534.38%
Operating Expenses to Revenue	2,792.58%	2,235.66%	1,895.79%	595.58%	789.79%	837.21%
Earnings before Interest and Taxes (EBIT)	-62	-85	-186	-239	-332	-465
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-60	-81	-178	-228	-308	-428
Valuation Ratios	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	5.33	3.01	4.61	1.87
Price to Tangible Book Value (P/TBV)	0.00	0.00	5.35	3.02	5.70	3.52
Price to Revenue (P/Rev)	188.17	110.14	284.42	36.68	47.92	32.93
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	68.42	0.00	24.97	2.94
Enterprise Value to Revenue (EV/Rev)	0.00	160.46	234.51	22.86	39.09	23.25
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-
Debt to Equity	0.00	0.06	0.02	0.00	0.00	0.03
Long-Term Debt to Equity	0.00	0.06	0.02	0.00	0.00	0.02
Financial Leverage	0.00	-1.03	-0.96	-1.03	-0.99	-0.64
Leverage Ratio	0.00	1.23	1.16	1.28	1.43	1.40
Compound Leverage Factor	0.00	1.23	1.16	1.28	1.43	1.40
Debt to Total Capital	0.00%	5.91%	1.82%	0.13%	0.25%	2.58%
Short-Term Debt to Total Capital	0.00%	0.42%	0.02%	0.02%	0.01%	0.79%
Long-Term Debt to Total Capital	0.00%	5.49%	1.80%	0.11%	0.24%	1.79%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	174.29%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	0.00%	-80.20%	98.18%	99.87%	99.75%	97.42%
Debt to EBITDA	0.00	-0.19	-0.06	0.00	0.00	-0.06
Net Debt to EBITDA	0.00	3.09	2.85	2.42	1.28	1.33
Long-Term Debt to EBITDA	0.00	-0.18	-0.06	0.00	0.00	-0.04
Debt to NOPAT	0.00	-0.26	-0.08	0.00	0.00	-0.08
Net Debt to NOPAT	0.00	4.20	3.97	3.20	1.61	1.70
Long-Term Debt to NOPAT	0.00	-0.24	-0.08	0.00	0.00	-0.06
Altman Z-Score	0.00	3.68	24.82	2.53	3.69	0.84
Noncontrolling Interest Sharing Ratio	0.00%	185.24%	57.11%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-
Current Ratio	0.00	11.53	11.46	5.68	4.70	3.81
Quick Ratio	0.00	11.35	11.27	5.51	4.24	3.43
Cash Flow Metrics	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-52	-170	-72	-380	-730
Operating Cash Flow to CapEx	-1,458.87%	-778.58%	-398.55%	-225.38%	-2,407.19%	-2,622.67%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-
Asset Turnover	0.00	0.01	0.02	0.06	0.07	0.06
Accounts Receivable Turnover	0.00	25.40	2.20	6.73	15.25	2.25
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.15	0.22	0.52	0.51	0.52
Accounts Payable Turnover	0.00	0.00	0.00	13.04	9.97	3.54
Days Sales Outstanding (DSO)	0.00	14.37	165.79	54.25	23.94	162.09
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	27.99	36.59	103.14
Cash Conversion Cycle (CCC)	0.00	14.37	165.79	26.25	-12.65	58.96
Capital & Investment Metrics	-	-	-	-	-	-
Invested Capital	0.00	-6.91	35	-65	70	465
Invested Capital Turnover	0.00	-1.15	0.73	-2.67	17.73	0.22
Increase / (Decrease) in Invested Capital	0.00	-6.91	42	-100	135	395
Enterprise Value (EV)	0.00	636	2,387	911	1,742	1,368
Market Capitalization	436	436	2,895	1,461	2,136	1,938
Book Value per Share	$0.00	($9.47)	$3.21	$2.56	$2.14	$3.61
Tangible Book Value per Share	$0.00	($9.59)	$3.20	$2.55	$1.73	$1.92
Total Capital	0.00	257	553	486	465	1,062
Total Debt	0.00	15	10	0.63	1.14	27
Total Long-Term Debt	0.00	14	9.97	0.54	1.10	19
Net Debt	0.00	-249	-508	-551	-394	-570
Capital Expenditures (CapEx)	3.91	5.83	40	37	12	14
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.00	-20	-30	-82	-50	-62
Debt-free Net Working Capital (DFNWC)	0.00	244	488	470	345	535
Net Working Capital (NWC)	0.00	243	488	470	345	527
Net Nonoperating Expense (NNE)	18	28	59	67	83	128
Net Nonoperating Obligations (NNO)	0.00	-249	-508	-551	-394	-570
Total Depreciation and Amortization (D&A)	2.49	3.94	8.41	12	24	36
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	-497.60%	-294.40%	-204.67%	-111.70%	-105.67%
Debt-free Net Working Capital to Revenue	0.00%	6,168.88%	4,796.13%	1,178.74%	773.99%	909.64%
Net Working Capital to Revenue	0.00%	6,141.80%	4,795.24%	1,178.50%	773.90%	895.32%
Earnings Adjustments	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	($1.49)	($1.36)	($1.58)	($1.69)
Adjusted Weighted Average Basic Shares Outstanding	0.00	0.00	125.35M	175.54M	207.85M	274.21M
Adjusted Diluted Earnings per Share	$0.00	$0.00	($1.49)	($1.36)	($1.58)	($1.69)
Adjusted Weighted Average Diluted Shares Outstanding	0.00	0.00	125.35M	175.54M	207.85M	274.21M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	0.00	170.77M	191.23M	234.65M	401.99M
Normalized Net Operating Profit after Tax (NOPAT)	-44	-59	-128	-172	-245	-335
Normalized NOPAT Margin	-1,884.81%	-1,494.96%	-1,257.05%	-431.72%	-549.73%	-569.86%
Pre Tax Income Margin	-2,692.58%	-2,135.66%	-1,832.18%	-601.05%	-745.10%	-789.93%
Debt Service Ratios	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Recursion Pharmaceuticals' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	419.34%	439.91%	127.53%	43.56%	-19.96%	-20.36%	13.68%	30.86%	147.62%	-58.26%
EBITDA Growth	-35.52%	7.90%	-15.76%	-12.27%	-43.39%	-54.94%	-37.62%	-25.16%	-3.56%	-85.41%
EBIT Growth	-34.85%	6.12%	-16.70%	-15.92%	-48.65%	-59.16%	-41.06%	-27.81%	-2.86%	-84.32%
NOPAT Growth	-34.85%	6.12%	-24.80%	-23.45%	-59.09%	-62.23%	-37.89%	-23.04%	1.20%	-85.75%
Net Income Growth	-27.45%	11.46%	-16.70%	-17.03%	-53.89%	-61.75%	-39.87%	-27.13%	-3.04%	-92.38%
EPS Growth	-25.00%	-350.00%	-3.03%	0.00%	-22.86%	-43.33%	-14.71%	-5.26%	20.93%	-30.23%
Operating Cash Flow Growth	-65.04%	26.83%	-194.74%	-9.48%	-33.70%	-65.54%	-39.53%	-21.87%	18.78%	-55.82%
Free Cash Flow Firm Growth	182.32%	165.26%	-248.98%	-516.81%	-590.22%	-457.82%	-102.85%	25.14%	24.06%	-156.98%
Invested Capital Growth	-582.84%	-285.61%	56.85%	177.90%	173.79%	207.77%	342.11%	126.23%	147.13%	566.12%
Revenue Q/Q Growth	71.49%	3.92%	-11.28%	-9.21%	-4.39%	3.40%	26.66%	4.52%	80.91%	-82.57%
EBITDA Q/Q Growth	6.03%	3.05%	-6.63%	-15.56%	-20.03%	-4.76%	7.23%	-5.10%	0.69%	-87.56%
EBIT Q/Q Growth	5.47%	2.54%	-7.13%	-17.45%	-21.23%	-4.34%	6.85%	-6.41%	2.44%	-86.99%
NOPAT Q/Q Growth	5.47%	2.54%	-14.57%	-16.96%	-21.83%	0.62%	2.62%	-4.36%	2.18%	-86.84%
Net Income Q/Q Growth	7.80%	4.89%	-13.63%	-17.45%	-21.23%	0.02%	1.75%	-6.75%	1.74%	-86.67%
EPS Q/Q Growth	7.89%	14.29%	-13.33%	-11.76%	-13.16%	0.00%	9.30%	-2.56%	15.00%	-64.71%
Operating Cash Flow Q/Q Growth	11.49%	17.96%	-63.84%	7.98%	-8.08%	-1.59%	-38.10%	19.63%	27.97%	-94.90%
Free Cash Flow Firm Q/Q Growth	-19.24%	48.55%	-284.06%	-88.77%	5.02%	-8.43%	-4.34%	30.33%	3.65%	-266.92%
Invested Capital Q/Q Growth	13.95%	4.84%	34.46%	245.14%	-18.49%	38.98%	47.25%	35.62%	-10.96%	274.61%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	-17.09%	20.74%	-2.59%	14.84%	-3.27%	9.28%	19.05%	36.19%	53.69%	-181.43%
EBITDA Margin	-452.77%	-422.40%	-507.66%	-646.12%	-811.16%	-821.83%	-614.58%	-617.99%	-339.23%	-3,650.40%
Operating Margin	-475.48%	-445.91%	-575.78%	-741.72%	-945.12%	-908.36%	-698.42%	-697.39%	-377.10%	-4,042.39%
EBIT Margin	-475.48%	-445.91%	-538.38%	-696.43%	-883.10%	-891.18%	-668.06%	-680.19%	-366.82%	-3,935.28%
Profit (Net Income) Margin	-459.31%	-420.39%	-538.38%	-696.43%	-883.10%	-853.88%	-662.41%	-676.56%	-367.46%	-3,935.46%
Tax Burden Percent	96.60%	105.04%	100.00%	100.00%	100.00%	95.81%	99.15%	99.47%	100.17%	100.00%
Interest Burden Percent	100.00%	89.75%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	-11,271.92%	-749.53%	-241.16%	-197.44%	-622.86%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	-11,266.89%	-743.32%	-234.78%	-190.59%	-612.43%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	11,207.20%	689.39%	189.99%	156.08%	393.89%
Return on Equity (ROE)	-50.03%	-46.56%	-53.87%	-57.36%	-70.84%	-64.72%	-60.14%	-51.16%	-41.36%	-228.97%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	-541.04%	-670.65%	-543.95%	-397.81%	-352.83%	-401.38%	-273.23%
Operating Return on Assets (OROA)	-21.49%	-27.09%	-36.88%	-51.99%	-67.33%	-58.63%	-52.12%	-46.81%	-35.23%	-220.28%
Return on Assets (ROA)	-20.76%	-25.54%	-36.88%	-51.99%	-67.33%	-56.18%	-51.68%	-46.56%	-35.29%	-220.29%
Return on Common Equity (ROCE)	-50.03%	-46.56%	-53.87%	-57.36%	-70.84%	-64.72%	-60.14%	-51.16%	-41.36%	-228.97%
Return on Equity Simple (ROE_SIMPLE)	-63.63%	0.00%	-57.84%	-55.44%	-66.80%	0.00%	-88.27%	-64.15%	-72.01%	0.00%
Net Operating Profit after Tax (NOPAT)	-44	-43	-49	-57	-70	-69	-67	-70	-69	-129
NOPAT Margin	-332.84%	-312.13%	-403.05%	-519.20%	-661.59%	-635.86%	-488.89%	-488.17%	-263.97%	-2,829.67%
Net Nonoperating Expense Percent (NNEP)	-3.20%	-2.80%	-3.09%	-4.23%	-5.53%	-5.03%	-6.21%	-6.37%	-6.85%	-10.43%
Return On Investment Capital (ROIC_SIMPLE)	-	-8.78%	-	-	-	-14.91%	-	-	-	-12.11%
Cost of Revenue to Revenue	117.09%	79.26%	102.59%	85.16%	103.27%	90.72%	80.95%	63.81%	46.31%	281.43%
SG&A Expenses to Revenue	148.09%	145.06%	188.51%	256.79%	277.21%	279.67%	227.69%	220.80%	144.76%	1,697.89%
R&D to Revenue	310.30%	321.59%	384.68%	499.77%	664.64%	637.98%	489.78%	512.78%	286.02%	2,163.07%
Operating Expenses to Revenue	458.39%	466.64%	573.19%	756.56%	941.86%	917.65%	717.47%	733.59%	430.78%	3,860.95%
Earnings before Interest and Taxes (EBIT)	-63	-61	-65	-77	-93	-97	-92	-98	-96	-179
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-60	-58	-62	-71	-85	-90	-85	-89	-88	-166
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	4.75	3.01	2.97	3.06	3.77	4.61	5.83	3.05	3.53	1.87
Price to Tangible Book Value (P/TBV)	4.77	3.02	2.98	3.93	4.77	5.70	7.40	3.61	4.23	3.52
Price to Revenue (P/Rev)	64.17	36.68	27.35	28.75	34.82	47.92	50.60	35.91	28.42	32.93
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	16.71	25.12	24.97	19.86	9.60	11.70	2.94
Enterprise Value to Revenue (EV/Rev)	48.27	22.86	17.21	20.60	26.64	39.09	44.15	26.94	22.28	23.25
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.05	0.05	0.03
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.04	0.04	0.02
Financial Leverage	-1.05	-1.03	-1.15	-1.02	-1.02	-0.99	-0.93	-0.81	-0.82	-0.64
Leverage Ratio	1.29	1.28	1.47	1.48	1.50	1.43	1.43	1.37	1.41	1.40
Compound Leverage Factor	1.29	1.14	1.47	1.48	1.50	1.43	1.43	1.37	1.41	1.40
Debt to Total Capital	0.17%	0.13%	0.43%	0.39%	0.41%	0.25%	0.28%	5.04%	5.19%	2.58%
Short-Term Debt to Total Capital	0.02%	0.02%	0.15%	0.14%	0.16%	0.01%	0.01%	1.32%	1.49%	0.79%
Long-Term Debt to Total Capital	0.14%	0.11%	0.27%	0.25%	0.26%	0.24%	0.27%	3.72%	3.71%	1.79%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	99.83%	99.87%	99.57%	99.61%	99.59%	99.75%	99.72%	94.96%	94.81%	97.42%
Debt to EBITDA	0.00	0.00	-0.01	-0.01	-0.01	0.00	0.00	-0.09	-0.08	-0.06
Net Debt to EBITDA	1.91	2.42	2.00	1.57	1.33	1.28	0.90	1.28	1.14	1.33
Long-Term Debt to EBITDA	0.00	0.00	-0.01	0.00	0.00	0.00	0.00	-0.07	-0.06	-0.04
Debt to NOPAT	0.00	0.00	-0.01	-0.01	-0.01	0.00	0.00	-0.11	-0.10	-0.08
Net Debt to NOPAT	2.61	3.20	2.60	2.12	1.77	1.61	1.13	1.61	1.45	1.70
Long-Term Debt to NOPAT	0.00	0.00	-0.01	-0.01	-0.01	0.00	0.00	-0.08	-0.07	-0.06
Altman Z-Score	4.10	3.37	2.80	2.98	3.38	4.87	6.42	3.82	3.35	1.50
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	5.80	5.68	5.34	3.78	4.36	4.70	4.65	6.07	4.35	3.81
Quick Ratio	5.62	5.51	5.16	3.59	4.15	4.24	4.04	5.54	3.95	3.43
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	38	57	-105	-198	-188	-204	-213	-148	-143	-524
Operating Cash Flow to CapEx	-660.06%	-560.82%	-1,416.73%	-1,700.28%	-9,787.92%	-3,583.79%	-1,537.65%	-6,955.92%	-1,298.22%	-8,892.91%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.05	0.06	0.07	0.07	0.08	0.07	0.08	0.07	0.10	0.06
Accounts Receivable Turnover	4.12	6.73	6.93	6.79	6.40	15.25	19.86	17.80	24.06	2.25
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.41	0.52	0.58	0.58	0.55	0.51	0.52	0.57	0.76	0.52
Accounts Payable Turnover	7.33	13.04	12.59	18.27	10.68	9.97	8.82	14.06	12.97	3.54
Days Sales Outstanding (DSO)	88.50	54.25	52.64	53.78	57.03	23.94	18.38	20.51	15.17	162.09
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	49.80	27.99	29.00	19.97	34.18	36.59	41.36	25.95	28.14	103.14
Cash Conversion Cycle (CCC)	38.69	26.25	23.64	33.81	22.85	-12.65	-22.99	-5.45	-12.96	58.96
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	-68	-65	-42	62	50	70	103	139	124	465
Invested Capital Turnover	-1.06	-2.67	-0.66	-5.72	-5.31	17.73	1.53	0.49	0.75	0.22
Increase / (Decrease) in Invested Capital	-82	-100	56	141	118	135	145	78	74	395
Enterprise Value (EV)	1,385	911	803	1,030	1,261	1,742	2,041	1,337	1,452	1,368
Market Capitalization	1,842	1,461	1,276	1,437	1,649	2,136	2,339	1,782	1,853	1,938
Book Value per Share	$2.24	$2.56	$2.25	$2.44	$2.03	$2.14	$1.71	$2.46	$1.87	$3.61
Tangible Book Value per Share	$2.23	$2.55	$2.24	$1.90	$1.60	$1.73	$1.35	$2.08	$1.56	$1.92
Total Capital	389	486	432	471	440	465	402	615	553	1,062
Total Debt	0.66	0.63	1.84	1.83	1.82	1.14	1.13	31	29	27
Total Long-Term Debt	0.56	0.54	1.18	1.16	1.13	1.10	1.07	23	21	19
Net Debt	-456	-551	-473	-407	-388	-394	-298	-445	-400	-570
Capital Expenditures (CapEx)	8.26	7.98	5.18	3.97	0.75	2.07	6.65	1.18	4.56	1.30
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-58	-82	-74	-91	-72	-50	-30	-32	-56	-62
Debt-free Net Working Capital (DFNWC)	399	470	401	318	317	345	270	444	374	535
Net Working Capital (NWC)	399	470	400	317	316	345	270	436	365	527
Net Nonoperating Expense (NNE)	17	15	16	20	23	24	24	27	27	50
Net Nonoperating Obligations (NNO)	-456	-551	-473	-407	-388	-394	-298	-445	-400	-570
Total Depreciation and Amortization (D&A)	2.99	3.21	3.73	5.54	7.58	7.55	7.38	8.97	7.20	13
Debt-free, Cash-free Net Working Capital to Revenue	-202.30%	-204.67%	-158.26%	-182.96%	-153.04%	-111.70%	-64.39%	-63.91%	-85.45%	-105.67%
Debt-free Net Working Capital to Revenue	1,389.12%	1,178.74%	858.92%	635.64%	669.55%	773.99%	583.43%	895.34%	573.00%	909.64%
Net Working Capital to Revenue	1,388.79%	1,178.50%	857.51%	634.29%	668.08%	773.90%	583.31%	879.00%	560.39%	895.32%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.35)	($0.30)	($0.34)	($0.38)	($0.43)	($0.43)	($0.39)	($0.40)	($0.34)	($0.56)
Adjusted Weighted Average Basic Shares Outstanding	173.44M	175.54M	191.62M	201.42M	214.33M	207.85M	236.02M	242.20M	282.58M	274.21M
Adjusted Diluted Earnings per Share	($0.35)	($0.30)	($0.34)	($0.38)	($0.43)	($0.43)	($0.39)	($0.40)	($0.34)	($0.56)
Adjusted Weighted Average Diluted Shares Outstanding	173.44M	175.54M	191.62M	201.42M	214.33M	207.85M	236.02M	242.20M	282.58M	274.21M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	189.56M	191.23M	192.36M	215.59M	216.62M	234.65M	237.66M	281.11M	286.64M	401.99M
Normalized Net Operating Profit after Tax (NOPAT)	-44	-43	-49	-57	-70	-69	-67	-70	-69	-129
Normalized NOPAT Margin	-332.84%	-312.13%	-403.05%	-519.20%	-661.59%	-635.86%	-488.89%	-488.17%	-263.97%	-2,829.67%
Pre Tax Income Margin	-475.48%	-400.21%	-538.38%	-696.43%	-883.10%	-891.18%	-668.06%	-680.19%	-366.82%	-3,935.28%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Recursion Pharmaceuticals' Financials

When does Recursion Pharmaceuticals's fiscal year end?

According to the most recent income statement we have on file, Recursion Pharmaceuticals' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Recursion Pharmaceuticals' net income changed over the last 5 years?

Recursion Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of -$463.66 million in 2024, rising from -$61.88 million in 2019. The previous period was -$328.07 million in 2023.

What is Recursion Pharmaceuticals's operating income?

Recursion Pharmaceuticals's total operating income in 2024 was -$479.00 million, based on the following breakdown:

Total Gross Profit: $13.60 million
Total Operating Expenses: $492.61 million

How has Recursion Pharmaceuticals revenue changed over the last 5 years?

Over the last 5 years, Recursion Pharmaceuticals' total revenue changed from $2.32 million in 2019 to $58.84 million in 2024, a change of 2,437.3%.

How much debt does Recursion Pharmaceuticals have?

Recursion Pharmaceuticals' total liabilities were at $413.82 million at the end of 2024, a 117.5% increase from 2023, and a 631.6% increase since 2020.

How much cash does Recursion Pharmaceuticals have?

In the past 4 years, Recursion Pharmaceuticals' cash and equivalents has ranged from $262.13 million in 2020 to $594.35 million in 2024, and is currently $594.35 million as of their latest financial filing in 2024.

How has Recursion Pharmaceuticals' book value per share changed over the last 5 years?

Over the last 5 years, Recursion Pharmaceuticals' book value per share changed from 0.00 in 2019 to 3.61 in 2024, a change of 361.0%.

Remove Ads

Related Companies

This page (NASDAQ:RXRX) was last updated on 4/16/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Recursion Pharmaceuticals (RXRX) Financials

Frequently Asked Questions About Recursion Pharmaceuticals' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Recursion Pharmaceuticals (RXRX) Financials

Annual Income Statements for Recursion Pharmaceuticals

Quarterly Income Statements for Recursion Pharmaceuticals

Annual Cash Flow Statements for Recursion Pharmaceuticals

Quarterly Cash Flow Statements for Recursion Pharmaceuticals

Annual Balance Sheets for Recursion Pharmaceuticals

Quarterly Balance Sheets for Recursion Pharmaceuticals

Annual Metrics and Ratios for Recursion Pharmaceuticals

Quarterly Metrics and Ratios for Recursion Pharmaceuticals

Frequently Asked Questions About Recursion Pharmaceuticals' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools